Femme et Homme
- | Pays :
- Korea, Republic of
- | Organes : -
- | Spécialités : -
Extrait
To identify the following items through the post marketing surveillance under routine clinical practice after marketing authorization of Brilinta Tablet: the occurrence of unrevealed Serious Adverse Events (SAEs), current status of occurrence of Adverse Events (AEs), the factors that may influence safety and efficacy of the drug.
Critère d'inclusion
- Acute Coronary Syndromes